2026 Cholesterol Guideline: ApoB and Lp(a) Go Mainstream

The Short Version: What Changed in March 2026

Here is the update in plain terms, as published:

This is a meaningful change in posture from the major cardiology bodies, and it is the kind of development worth understanding if you keep a longitudinal record of your own biomarkers. Nothing here is medical guidance, and every recommendation described belongs to the guideline authors, not to us.

What ApoB Actually Measures

A standard lipid panel reports cholesterol mass: how much cholesterol is carried inside particles like [LDL-C](/biomarkers/ldl-c) and [HDL-C](/biomarkers/hdl-c). [ApoB](/biomarkers/apob), or apolipoprotein B, works differently. Every atherogenic particle that can deposit cholesterol in an artery wall carries exactly one ApoB molecule. So measuring ApoB counts the number of atherogenic particles directly, rather than estimating the cholesterol mass those particles carry.

That distinction is precisely why the guideline highlights ApoB for residual risk assessment. Two people can have the same LDL-C number but a very different particle count. Someone with many small, cholesterol-poor particles can have a "normal looking" LDL-C while carrying a high particle burden, and it is the particle count that ApoB captures. For people who have already hit their LDL-C goal but fall into a higher-risk group, the guideline points to ApoB as a way to see what the standard number can miss.

The phrase the guideline uses is "residual risk," meaning the risk that remains after LDL-C has been brought to goal. The named groups are specific: cardiometabolic syndrome, type 2 diabetes, high [triglycerides](/biomarkers/triglycerides), or established cardiovascular disease. Those are the populations in which the discrepancy between cholesterol mass and particle count tends to matter most, which is the rationale the guideline gives for measuring ApoB there.

What Lp(a) Actually Measures, and Why Once Is Enough

Lp(a), spoken as "lipoprotein little a," is a particle that resembles LDL but carries an extra protein attached to it. What makes Lp(a) distinctive for tracking purposes is that it is largely genetically determined. Your level is set mostly by the genes you inherited, and unlike many lipid markers, it does not respond much to diet, exercise, or the usual lifestyle levers.

That single fact drives the guideline's recommendation. Because lifestyle changes barely move Lp(a), the guideline says measuring it at least once in adulthood is generally sufficient, and repeat testing is usually unnecessary. This is a different testing philosophy from markers that fluctuate. You track [HbA1c](/biomarkers/hba1c) or [hs-CRP](/biomarkers/hs-crp) repeatedly because they change with what you do. You measure Lp(a) essentially once because, for most people, it does not change in a way repeat testing would catch.

For someone building a personal lab history, that is a useful framing. Lp(a) becomes a one-time entry in your record, a fixed coordinate rather than a trend line, while most of your other markers remain things you compare over time.

ApoB and Lp(a) Versus the Standard Panel

The table below organizes how these two newly recommended markers compare with the familiar lipid numbers. It reflects the guideline's framing, not any interpretation of your individual results.

|---|---|---|

A point worth stating plainly: this guideline describes which measurements to consider and how often, in defined populations. It is the cardiology societies' framework for assessing risk, and it is published as a recommendation set. Whether any of it applies to you is a clinical judgment that belongs to your provider, who can weigh your full history. MyProtocolStack is where you keep the record organized; it is not where the medical interpretation happens.

Why This Reframes "Advanced" Lipid Testing

For years, ApoB and Lp(a) sat in a slightly awkward place. Engaged individuals tracking their own health frequently asked for them, sometimes paying out of pocket, while the tests were often described as advanced, optional, or beyond standard care. The 2026 guideline changes that conversation by giving both markers explicit, society-backed recommendations within defined groups.

The reframe matters for a practical reason. When a marker moves from "something enthusiasts order" to "something a multi-society guideline recommends," it tends to become easier to discuss with a clinician and easier to fit into a coherent monitoring plan. The guideline did not invent these tests; ApoB and Lp(a) have been measurable for a long time. What changed is their status. The first new dyslipidemia guideline in eight years put them on record, with specific rationale: ApoB because it counts particles directly rather than estimating cholesterol mass, and Lp(a) because its genetic basis makes a single lifetime measurement informative.

That is the entire significance for people who track their data. The markers you may already have been curious about now come with a published rationale you can bring to a provider conversation, rather than a hunch.

This change also fits a larger 2026 pattern of formalizing tests and frameworks that data-driven individuals adopted ahead of the mainstream. A multi-society guideline carries weight precisely because it represents consensus across the ACC, the AHA, and 10 partner organizations rather than a single group's opinion. When that many bodies put ApoB and Lp(a) on the record, it signals that the underlying science, particle count for ApoB and genetic determination for Lp(a), reached a threshold of agreement. The practical takeaway is steady regardless of how the details evolve: keep your lab records clean, connected, and provider-ready, with ApoB in its residual-risk role and Lp(a) as a once-in-adulthood entry.

What to Track: Biomarkers Worth Monitoring

Whether you are early in building a lab history or you already keep a detailed record, the 2026 guideline gives a clean reason to make sure your lipid-related data is organized and provider-ready. The following are markers that the guideline and standard cardiometabolic monitoring commonly involve. None of this is a recommendation to test or treat; it is a list of what is commonly tracked so you can organize your own data and compare it over time with your provider.

Tracking these consistently, as a connected history rather than scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot; a trend line tells a story, and in the case of Lp(a), even a single well-recorded value has lasting use. You can browse plain-language explanations of each test in the full [biomarker library](/biomarkers).

[Track your lipid panel and lab history in one place with MyProtocolStack.](/auth/login?mode=signup)

For people who track their health seriously, the practical takeaway is steady regardless of how the details evolve: keep your lab records clean, connected, and provider-ready. The guideline gives ApoB a defined role in residual-risk assessment and gives Lp(a) a once-in-adulthood place in your history. Your job, on the tracking side, is to make sure those values live in one organized record you can compare over time and bring to the clinician who manages your care. You can explore the full set of markers in the [biomarker library](/biomarkers) whenever you want plain-language context.

Frequently Asked Questions

What did the 2026 ACC/AHA dyslipidemia guideline change about ApoB and Lp(a) testing?

On March 13, 2026, the ACC, AHA, and 10 partner societies published the first new dyslipidemia guideline since 2018. It formally recommends measuring ApoB to assess residual risk in people with cardiometabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have already reached their LDL-C goal. It also recommends measuring Lp(a) at least once in adulthood. This moves both markers from being viewed as fringe advanced tests to being guideline-backed. The guideline is a published recommendation set, and whether any of it applies to you is a decision for your provider.

Why does the guideline recommend ApoB instead of just LDL-C?

ApoB counts atherogenic particles directly, because every atherogenic particle carries exactly one ApoB molecule, whereas LDL-C estimates the cholesterol mass those particles carry. Two people with the same LDL-C can have a very different particle count, and the guideline highlights ApoB for residual-risk assessment in higher-risk groups who have already reached their LDL-C goal. It is positioned as a way to see risk that the standard cholesterol-mass number can miss, not as a replacement for clinical judgment.

Why is Lp(a) only measured once in a lifetime?

Lp(a) is largely genetically determined, so your level is set mostly by inherited genes rather than by diet or exercise. Because lifestyle changes barely move Lp(a), the 2026 guideline says measuring it at least once in adulthood is generally sufficient and that repeat testing is usually unnecessary. For tracking purposes, that makes Lp(a) a one-time fixed entry in your lab history rather than a marker you compare over time.

Are ApoB and Lp(a) still considered advanced or fringe tests?

The 2026 guideline reframes them. Both markers were long requested by optimizers as advanced lipid tests, and the new guideline gives each an explicit recommendation within defined populations. That shifts them from enthusiast-ordered extras to guideline-backed measurements. The tests themselves are not new; what changed is their status within a major multi-society guideline, which can make them easier to discuss with a clinician.

Does MyProtocolStack tell me what my ApoB or Lp(a) results mean?

No. MyProtocolStack is a tracking and education tool. It helps you organize your lab history, including ApoB and Lp(a), so you can visualize it and compare it over time, but it does not diagnose, interpret your cardiovascular risk, or recommend therapy. The recommendations described here belong to the 2026 guideline authors. Any interpretation of your individual results, and any decision about testing or treatment, is for your provider or prescriber.

Sources

1. American College of Cardiology, "ACC/AHA Release New Clinical Guideline for Managing Dyslipidemia," March 13, 2026. https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia

2. Circulation (AHA Journals), 2026 ACC/AHA/Multisociety Guideline for the Management of Dyslipidemia. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423

3. National Lipid Association, "2026 ACC/AHA/Multisociety Dyslipidemia Guideline Released." https://www.lipid.org/nla/2026-accahamultisociety-dyslipidemia-guideline-released

4. HCPLive, "Expert Insights: Lp(a) and ApoB in the 2026 Dyslipidemia Guidelines." https://www.hcplive.com/view/expert-insights-lp-a-and-apob-in-the-2026-dyslipidemia-guidelines

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*